The first oral rescue therapy for acute attacks is on the horizon.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.